Fig. 3
From: Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice
Metformin reduced NP tau aggregation in PS19BE-injected APP/PS1 mice. a Representative images of NP tau burden labeled with AT8 (a), AT180 (b), or p-Tau 422 (c) surrounding Aβ burden labeled with 6E10 (a) or 4G8 (b, c) in PS19BE-injected APP/PS1 mice treated with or without metformin. Scale bars, 50 μm. d–f Quantification of NP tau in PS19BE-injected APP/PS1 mice treated with or without metformin. Data were analyzed by Student’s t test. Values are presented as mean±SEM. n = 5 per group. #P < 0.05 vs. tau+veh group